Roche says Tecentriq, chemo cut risk of death in type of lung cancer

ZURICH (Reuters) – Roche’s immunotherapy Tecentriq plus chemotherapy cut the risk of disease worsening or death in advanced squamous lung cancer, but it did not yet show an overall survival benefit in this tough-to-treat disease, the Swiss drugmaker said Tuesday.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply